Aberrant mTOR activation is a hallmark of gliomas and is driven by upstream alterations such as EGFR amplification, PTEN loss, and PI3K mutations, all converging to increase signaling through the PI3K-Akt-mTOR pathway [100,101,102,103]. The gene discussed is MTOR; the disease is central nervous system cancer.